fashion -WSS

fashion

author：knowledge 2025-10-01 23:01:00 - browse：56254

Jakub Porzycki/NurPhoto via AP

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Hello, everyone. Damian here with the fallout from Pfizer’s downbeat update, a new entrant in obesity research, and an orthogonal CRISPR business.

The need-to-know this morning

Apellis Pharmaceuticals said a European advisory committee is expected to recommend against the approval of Syfovre, its eye drug for a common form of blindness. The company plans to appeal the negative ruling.
Sage Therapeutics and Biogen announced the commercial launch of Zurzuvae, an oral treatment for women with postpartum depression.
Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for advanced melanoma. Phase 3 studies are underway.
The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to treat advanced small cell lung cancer. The approval decision date is June 12, 2024.

Is it time to worry about Moderna?

Yesterday’s news that Pfizer is expecting to sell far fewer Covid-19 vaccines than Wall Street expected sent shares of Moderna down as much as 6% on fears that the company could be in for a painful revision of its own.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Connecting traumatic brain injury and domestic violence

leisure time

WSS

Option Care buys Amedisys in $3.6 billion home care deal

Grail is spending more than ever lobbying Congress

Community addresses injustice for Long Island mothers

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Meta looks to target Twitter with a rival app called Threads

Designating disabled people as health disparity population is crucial

knowledge

fashion

The need-to-know this morning

Is it time to worry about Moderna?

explore

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

Guidelines to prevent youth baseball injuries need more muscle

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

At least 13 dead in Texas as scorching temps continue

4th of July breaks record for highest global temperature ever measured

Psychedelics group wrestles with new pharma identity

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Psychedelics group wrestles with new pharma identity

Designating disabled people as health disparity population is crucial

focus

HHS names first

Australia's humpback populations rebound raising hopes of marine scientists

Doudna institute plans to 'cure hundreds of diseases' with CRISPR

Why is France rioting? What to know about the fatal police shooting of Nahel M

Biotech reporter’s notebook: A sunnier mood at JPM 2024

Pfizer's Covid pill remains 89% effective in final analysis, company says

hotspot

leisure time

focus

hotspot